Erectile Dysfunction Drugs Market Analysis By Product (Viagra, Levitra/Staxyn, Stendra/Spedra, Zydena, Vitaros), And Segment Forecasts To 2022

Published: Nov, 2015 | Pages: 85 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global erectile dysfunction drugs market is expected to reach USD 3.2 billion by 2022 according to a new report by Grand View Research Inc. Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this market.

However, the market is estimated to witness decline in revenue over the forecast period. Expiration of key drugs from 2017 to 2019 is likely to curb revenue growth. On the other hand, the market is likely to open up new avenues for the generic manufacturers to capitalize on. The increasing risk of sexually transmitted diseases, narrowing of insurance coverage for erectile dysfunction treatment, growing threat from counterfeit drugs, and presence of social stigma in developing countries are some factors limiting penetration rates.

Further key findings from the report suggest:

Viagra accounted for over 47.0% of the total revenue in 2014. It is generally considered as the first line of treatment for erectile dysfunction. Brand loyalty and advantages associated with this drug such as high efficacy, and effectiveness are the major factors attributing for its large market share.
Cialis (tadalafil) from Eli Lilly & Co. and Levitra (vardenafil) from Bayer AG are known to be the competitors for Viagra globally. Cialis (tadalafil) was approved in 2003 by the U.S. FDA, as a prescription drug in the U.S. Cialis is also known as "The Weekend Pill" owing to its 36-hour effectiveness.
After the patent expiration of key drugs such as Cialis (tadalafil) in 2017 and Levitra (vardenafil) in 2018, other drugs such as Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil Cream) are expected to capture the market share during the forecasts period.
North America constituted the largest share of approximately 55.0% in 2013 of the total erectile dysfunction market. Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along with introduction of new erectile dysfunction drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors responsible for market growth during the forecasts period.
Asia Pacific accounted for a revenue share of over 16.5% in 2012 owing to the presence of a lucrative market for generic drugs, untapped opportunities, and increasing awareness related to erectile dysfunction in this region
Apricus Biosciences Inc., Cristalia Produtos Quimicos Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals Co. Ltd., and Vivus, Inc. are some major players of this market
Extensive R&D carried out by companies and high unmet needs in developing economies are expected to boost industrial growth. Key manufacturers are targeting regions with unmet clinical needs by entering into agreement with local manufacturers and distributors. Key players are constantly engaged in developing novel drugs in an attempt to improve the presence and ensure sustainability.

Table of Content

Chapter 1. Methodology and Scope
1.1. Research methodology
1.2. Research scope & assumption
1.3. List of data sources
Chapter 2. Executive Summary
2.1. Erectile Dysfunction Drugs - Industry Summary and Key Buying Criteria, 2012 - 2022
Chapter 3. Erectile Dysfunction Drugs Industry Outlook
3.1. Erectile dysfunction drugs market segmentation
3.2. Erectile dysfunction drugs market size and growth prospects, 2012-2022
3.3. Erectile dysfunction drugs market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. Erectile dysfunction drugs: Company market share, 2014
3.7. Erectile dysfunction drugs market PESTEL analysis, 2014
Chapter 4. Erectile Dysfunction Drugs Product Outlook
4.1. Erectile dysfunction drugs market share by product, 2014 & 2022
4.1.1. Viagra (sildenafil citrate) market estimates and forecasts, 2012 - 2022 (USD Million)
4.1.2. Cialis (Tadalafil) market estimates and forecasts, 2012 - 2022 (USD Million)
4.1.3. Levitra/Staxyn (vardenafil) market estimates and forecasts, 2012 - 2022 (USD Million)
4.1.4. Stendra/Spedra (avanafil) estimates and forecasts, 2012 - 2022 (USD Million)
4.1.5. Zydena (udenafil) market estimates and forecasts, 2012 - 2022 (USD Million)
4.1.6. Vitaros (Alprostadil Cream) market estimates and forecasts, 2012 - 2022 (USD Million)
4.1.7. Other drugs market estimates and forecasts, 2012 - 2022 (USD Million)
Chapter 5. Erectile Dysfunction Drugs Regional Outlook
5.1. North America
5.1.1. North America market, by product, 2012 - 2022 (USD Million)
5.2. Europe
5.2.1. Europe market, by product, 2012 - 2022 (USD Million)
5.3. Asia Pacific
5.3.1. Asia Pacific market, by product, 2012 - 2022 (USD Million)
5.4. Latin America
5.4.1. Latin America market, by product, 2012 - 2022 (USD Million)
5.5. MEA
5.5.1. MEA market, by product, 2012 - 2022 (USD Million)
Chapter 6. Competitive Landscape
6.1. Apricus Biosciences Inc.
6.1.1. Company Overview
6.1.2. Financial Performance
6.1.3. Product Benchmarking
6.1.4. Strategic Initiatives
6.2. Bayer AG
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Product Benchmarking
6.2.4. Strategic Initiatives
6.3. Cristalia Produtos Quimicos Farmaceuticos Ltd.
6.3.1. Company Overview
6.3.2. Financial Performance
6.3.3. Product Benchmarking
6.3.4. Strategic Initiatives
6.4. Dong-A Pharmaceutical Co. Ltd.
6.4.1. Company Overview
6.4.2. Financial Performance
6.4.3. Product Benchmarking
6.4.4. Strategic Initiatives
6.5. Eli Lilly and Company
6.5.1. Company Overview
6.5.2. Financial Performance
6.5.3. Product Benchmarking
6.5.4. Strategic Initiatives
6.6. Meda Pharmaceuticals, Inc.
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Product Benchmarking
6.6.4. Strategic Initiatives
6.7. Pfizer, Inc.
6.7.1. Company Overview
6.7.2. Financial Performance
6.7.3. Product Benchmarking
6.7.4. Strategic Initiatives
6.8. S.K. Chemicals Co. Ltd.
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Product Benchmarking
6.8.4. Strategic Initiatives
6.9. Vivus, Inc.
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Product Benchmarking
6.9.4. Strategic Initiatives

List of Tables

1. Erectile dysfunction drugs- Industry snapshot
2. Erectile dysfunction drugs market , by product, 2012 - 2022 (USD million)
3. Erectile dysfunction drugs market , by region, 2012 - 2022 (USD million)
4. Erectile dysfunction drugs market - Key market drivers analysis
5. Erectile dysfunction drugs market - Key market restraints analysis
6. North America erectile dysfunction drugs market , by Product, 2012 - 2022 (USD million)
7. Europe erectile dysfunction drugs market, by product, 2012 - 2022 (USD million)
8. Asia Pacific Erectile dysfunction drugs market, by product, 2012 - 2022 (USD million)
9. Latin America erectile dysfunction drugs market , by product, 2012 - 2022 (USD million)
10. MEA erectile dysfunction drugs market , by product, 2012 - 2022 (USD million)